Arch Biopartners Inc is a junior biotechnology company operating in the Canadian healthcare industry.
The clinical-stage company focuses on the development of new technologies to support the healthcare structure and its commercialization significantly.
The Toronto-based biotech firm provides a diversified portfolio of medical solutions catering to different diseases.
Metablok (LSALT peptide) is the firm’s lead drug candidate. Through this product, the healthcare firm aims to treat inflammation, sepsis and cancer metastasis in the lungs, liver, and kidneys.
In addition, it says that presently, the drug candidate is undergoing Phase II international trials in the United States and Turkey to measure its performance in preventing multiple organ injuries in patients affect with COVID-19.
AB569 is a new drug mechanized for the treatment of antibiotic-resistant bacterial infections, the medical company claims. It adds that the medicine has orphan drug status and is approved by the United States FDA and EMA (European Medicines Agency) for the treatment of P. aeruginosa-caused infections with patients suffering from cystic fibrosis. The bacteria causes infections in the patient’s respiratory tract, the medical technology firm claims.
The company claims that BORG is a collection of synthetic peptides (small chains of amino acids linked by peptide bonds) and peptide conjugates that react with solid surface and develop a peptide solid surface interface to create new materials, displaying new characteristics of the surface.
The medical firm says that its technology has applications in medical and life sciences companies and industrial applications, like corrosive process.
The Canadian clinical stage firm says that its MetaMx drug candidate comprises synthetic peptides that target and attach to tumor causing cells, including glioma cells and brain tumor initiating cell targeting (BTICs) for diagnosing, imaging and developing therapies for improving survivability and patient outcome in individuals affected with GBM, a type of fast-growing brain tumor.
Arch Biotech claims to work with various research institutes, scientific organizations and universities to discover, innovate and upgrade pre-clinical technologies.
In March 2021, the company reportedly signed a license agreement with the University of Cincinnati (UC) to develop a topical wound application version for AB569.
Further in April, the biotech firm entered into a global license agreement with Telara Pharma, a Spanish company, to develop and commercialize cilastatin to treat acute kidney injury clinically.